Cargando…

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants

Detalles Bibliográficos
Autores principales:	Zhao, Xin, Zheng, Anqi, Li, Dedong, Zhang, Rong, Sun, Huan, Wang, Qihui, Gao, George F, Han, Pengcheng, Dai, Lianpan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378832/ https://www.ncbi.nlm.nih.gov/pubmed/34458880 http://dx.doi.org/10.1016/S2666-5247(21)00217-2

Ejemplares similares

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation
por: Zhao, Yingze, et al.
Publicado: (2022)

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac
por: Chen, Yuxin, et al.
Publicado: (2021)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
por: Zhao, Xin, et al.
Publicado: (2022)

Preclinical Toxicity and Immunogenicity of a COVID-19 Vaccine (ZF2001) in Cynomolgus Monkeys
por: Yang, Hongzhong, et al.
Publicado: (2022)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Antisera by the Mouth
por: Basu, K. M.
Publicado: (1932)

Three-dose vaccination elicits neutralising antibodies against omicron
por: Wu, Mary, et al.
Publicado: (2022)

Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats
por: Song, Yisheng, et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
por: Dai, Lianpan, et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination
por: Zhang, Yuwei, et al.
Publicado: (2023)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19
por: Lu, Yingying, et al.
Publicado: (2022)

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

CoronaVac induces lower neutralising activity against variants of concern than natural infection
por: Vacharathit, Vimvara, et al.
Publicado: (2021)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
por: Li, Yang, et al.
Publicado: (2020)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Finite neutralisation breadth of omicron after repeated vaccination
por: Zhu, Yufang, et al.
Publicado: (2022)

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
por: Jansen van Vuren, Petrus, et al.
Publicado: (2022)

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant
por: Lee, Cheryl Yi‐Pin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_81ousqlb1d5ie8enmgecc1l4n6